Clinical Trials: A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay

Sponsor and Collaborators
Inova Health Care Services
Novartis Pharmaceuticals

Contacts
Joy Wiedemann, RN, BSN
703-776-4304
joy.wiedemann@inova.org

Stacey Banks, CCRC
703-776-3565 
stacey.banks@inova.org

Principal Investigator
Kirsten Edmiston, MD, FACS
Inova Fairfax Hospital Cancer Center

ClinicalTrials.gov Identifier 
NCT00867334


Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs